Table 1.
Demographic characteristics, vaccination status, and clinical classification of the case-case study subjects, Henan, 2 January 2022–23 January 2022.
| Variable | n (%) | ||
|---|---|---|---|
| Delta Infection N = 405 |
Omicron Infection N = 421 |
Total N = 826 |
|
| Gender | |||
| Female | 234 (57.8) | 239 (56.8) | 473 (57.3) |
| Male | 171 (42.2) | 182 (43.2) | 353 (42.7) |
| Age Group (years) | |||
| <18 | 60 (14.8) | 194 (46.1) | 254 (30.8) |
| 18–49 | 175 (43.2) | 172 (40.9) | 347 (42.0) |
| ≥50 | 170 (42.0) | 55 (13.0) | 225 (27.2) |
| Vaccination Status | |||
| Full primary vaccination <180 days | 220 (54.3) | 332 (78.9) | 552 (66.8) |
| Full primary vaccination ≥180 days | 120 (29.6) | 79 (18.7) | 199 (24.1) |
| Booster vaccination | 65 (16.1) | 10 (2.4) | 75 (9.1) |
| Vaccine Type | |||
| Inactivated vaccine | 374 (92.4) | 403 (95.7) | 777 (94.1) |
| CHO vaccine | 29 (7.1) | 16 (3.8) | 45 (5.4) |
| Ad5 vaccine | 2 (0.5) | 2 (0.5) | 4 (0.5) |
| Comorbidities | |||
| No | 352 (86.9) | 389 (92.4) | 741 (89.7) |
| Yes | 53 (13.1) | 32 (7.6) | 85 (10.3) |
| Pneumonia | |||
| No | 207 (51.1) | 341 (81.0) | 548 (66.3) |
| Yes | 198 (48.9) | 80 (19.0) | 278 (33.7) |
| Clinical Severity | |||
| Asymptomatic | 19 (4.7) | 37 (8.8) | 56 (6.8) |
| Mild | 186 (45.9) | 304 (72.2) | 490 (59.3) |
| Moderate | 195 (48.2) | 80 (19.0) | 275 (33.3) |
| Severe | 3 (0.7) | 0 | 3 (0.4) |
| Critical Severe | 2 (0.5) | 0 | 2 (0.2) |